Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV-2 With the Diagnosis, Disease Severity, and Antibody Titers in Patients With COVID-19: A Retrospective Cross-Sectional Study

Background: Several types of laboratory tests for COVID-19 have been established to date; however, the clinical significance of the serum SARS-CoV-2 nucleocapsid (N) antigen levels remains to be fully elucidated. In the present study, we attempted to elucidate the usefulness and clinical significance of the serum N antigen levels. Methods: We measured the serum N antigen levels in 391 serum samples collected from symptomatic patients with a confirmed diagnosis of COVID-19 and 96 serum samples collected from patients with non-COVID-19, using a fully automated chemiluminescence immunoassay analyzer. Results: Receiver operating characteristic analysis identified the optimal cutoff value of the serum N antigen level (cutoff index, based on Youden’s index) as 0.255, which yielded a sensitivity and specificity for the diagnosis of COVID-19 of 91.0 and 81.3%, respectively. The serum N antigen levels were significantly higher in the patient groups with moderate and severe COVID-19 than with mild disease. Moreover, a significant negative correlation was observed between the serum N antigen levels and the SARS-CoV-2 IgG antibody titers, especially in patients with severe COVID-19. Conclusion: Serum N antigen testing might be useful both for the diagnosis of COVID-19 and for obtaining a better understanding of the clinical features of the disease.

[1]  Yunbao Pan,et al.  High Performance of SARS-Cov-2N Protein Antigen Chemiluminescence Immunoassay as Frontline Testing for Acute Phase COVID-19 Diagnosis: A Retrospective Cohort Study , 2021, Frontiers in Medicine.

[2]  K. Moriya,et al.  Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples , 2021, PloS one.

[3]  V. Arankalle,et al.  Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India , 2021, The American journal of tropical medicine and hygiene.

[4]  G. Sourvinos,et al.  SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study , 2021, Viruses.

[5]  Yifan Meng,et al.  Dynamic Antibody Responses in Patients with Different Severity of COVID-19: A Retrospective Study , 2021, Infectious Diseases and Therapy.

[6]  Elizabeth B White,et al.  Delayed production of neutralizing antibodies correlates with fatal COVID-19 , 2021, Nature Medicine.

[7]  G. Matarese,et al.  Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients , 2021, Clinical Immunology.

[8]  H. Mikamo,et al.  Efficacy and validity of automated quantitative chemiluminescent enzyme immunoassay for SARS-CoV-2 antigen test from saliva specimen in the diagnosis of COVID-19 , 2021, Journal of Infection and Chemotherapy.

[9]  Joseph M. Johnson,et al.  N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection , 2021, Nature Communications.

[10]  M. Rasmussen,et al.  Antibody kinetics and clinical course of COVID-19 a prospective observational study , 2021, PloS one.

[11]  V. Arankalle,et al.  Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. , 2021, Viral immunology.

[12]  M. Maejima,et al.  Prospective study of 1308 nasopharyngeal swabs from 1033 patients using the LUMIPULSE SARS-CoV-2 antigen test: Comparison with RT-qPCR , 2021, International Journal of Infectious Diseases.

[13]  Y. Seto,et al.  Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan , 2021, Scientific Reports.

[14]  P. Alifano,et al.  IgM and IgG Profiles Reveal Peculiar Features of Humoral Immunity Response to SARS-CoV-2 Infection , 2021, International journal of environmental research and public health.

[15]  F. Cosset,et al.  A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity , 2021, Cellular & Molecular Immunology.

[16]  Inserm,et al.  Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives , 2020, Clinical Microbiology and Infection.

[17]  Chaolong Wang,et al.  Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19 , 2020, Annals of Internal Medicine.

[18]  R. Tibshirani,et al.  Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome , 2020, Science Immunology.

[19]  M. Hallek,et al.  Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia , 2020, Bone Marrow Transplantation.

[20]  T. Gibson,et al.  Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease , 2020, Clinical chemistry.

[21]  R. Kaiser,et al.  RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients , 2020, Viruses.

[22]  M. Maejima,et al.  Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients , 2020, International Journal of Infectious Diseases.

[23]  E. Albert,et al.  SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients , 2020, Journal of Clinical Virology.

[24]  F. Wang,et al.  Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity , 2020, Virologica Sinica.

[25]  Y. Seto,et al.  Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan , 2020, medRxiv.

[26]  Michael D Healy,et al.  SARS-CoV-2 viral load is associated with increased disease severity and mortality , 2020, Nature Communications.

[27]  R. Pontarolo,et al.  Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19 , 2020, American Journal of Infection Control.

[28]  Bifeng Liu,et al.  Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays , 2020, Clinical chemistry and laboratory medicine.

[29]  Melis N. Anahtar,et al.  Clinical sensitivity and interpretation of PCR and serological COVID‐19 diagnostics for patients presenting to the hospital , 2020, medRxiv.

[30]  Quanzhen Li,et al.  SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity , 2020, American journal of clinical pathology.

[31]  Jun Yuan,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[32]  A. Xu,et al.  Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019 , 2020, International Journal of Infectious Diseases.

[33]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[34]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.